Description
A Phase 3, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib Versus Ibrutinib as 1L+ Therapy in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)
Location: REDI (East Bay)
Contact: Chris Tang or 510.204.3428